Detection of antibodies interacting with glycosaminoglycan polysulfate in patients treated with heparin or other polysulfated glycosaminoglycans.
A new method has been developed for the demonstration of the antibody nature of a factor occurring in some patients during treatment with heparin or other polysulfated glycosaminoglycans (GAGPS). So far, antibodies reacting with GAGPS, except heparin, have not been described. We used heparin- or GAGPS-coated normal blood group O thrombocytes for the detection of suspected antibodies. After addition of patients' plasma or serum to a suspension of purified heparin- or GAGPS-coated platelets, agglutination was determined microscopically. In indirect immunofluorescence, positive staining of agglutinated platelets was observed with fluorescein isothiocyanate anti-Ig and anti-IgG conjugates, but not with anti-IgA or anti-IgM, with one exception in which IgM antibodies were also involved. Binding of complement was also shown using a tetramethylrhodamin isothiocyanate-labelled anti-C3 conjugate in double-staining experiments. Fibronectin could be excluded as a possible factor responsible for thrombocyte agglutination.
D005455:Fluorescent Antibody Technique; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis*; D010974:Platelet Aggregation; D013921:Thrombocytopenia / Q000188:drug therapy / Q000276:immunology*
D006025:Glycosaminoglycans; D007074:Immunoglobulin G; C013786:A73025; C010034:Arteparon; D006493:Heparin